the clinical research of D-CLAG regimen in the treatment of children with refractory or relapsed acute myeloid leukemia

the clinical research of modified D-CLAG regimen in the treatment of children with refractory or relapsed acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045432

Enrollment

Unknown

Registered

2021-04-14

Start date

2021-04-12

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

Experimental group:D-CLAG regime

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Relapsed or refractory AML included granulocytic sarcoma and MDS-RAEBT; 2. Aged <= 18 years; 3. Obtain the consent of the guardian or/and the child, and they sign the informed consent form; 4. The estimated survival time was more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Juvenile myelomonocytic leukemia (JMML); 2. AML secondary to Fanconi anemia (FA); 3. AML secondary to Down syndrome; 4. AML secondary to any other congenital disease; 5. Only temporary chemotherapy, radiotherapy or immunotherapy, but not systematic treatment according to the treatment plan; 6. Coexisting diseases or mental diseases with any significant abnormality affect the life safety and compliance of patients. 7. Patients with poor nutritional status, severe infection, cardiac insufficiency, and unable to tolerate chemotherapyts.

Design outcomes

Primary

Measure	Time frame
remission rate;overall survive;minimal residual disease;	—

Secondary

Measure	Time frame
mutate gene;	—

Countries

China

Contacts

Public ContactZhang Na

Shanghai Children's Hospital

abczhangna@hotmail.com+86 18101887300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026